Category Archives: HIV/AIDS

Combining structural, biomedical, behavioral responses to HIV can make difference for those at highest risks, and least access to services

By on .

Carlos Laudari had a splinter. He got it on his way to a lunch meeting at Pathfinder International’s Washington, DC office, and although he was looking forward to the talk over lunch, he told the group there, the splinter distracted him. Laudari uses a cane, is not a young man, and can surely put so […]

South Africa HIV incidence, prevalence, behavior survey raises questions

By on .

What does it mean when the country with the largest HIV epidemic in the world sees prevalence of the virus rise? In South Africa, one of the last countries in Africa to make treatment available to those who needed it and now home to the largest antiretroviral treatment program on earth, it means that more […]

Pediatric AIDS prevention trial that helped pave way for vision of AIDS-free generation is part of pioneering researcher’s story

By on .

This article originally appeared on the Elizabeth Glaser Pediatric AIDS Foundation blog Experts in Focus: Dr. Laura Guay By Chelsea Bailey | April 15, 2014 “When it comes to your career, I tell people, ‘you just don’t know.’ Something could come along and change your life, and for me, this was it.” -Laura Guay, M.D. […]

HIV/AIDS Community applauds Birx’s confirmation

By on .

Advocates began lauding the long-awaited confirmation of Dr. Deborah Birx as the new Global AIDS Ambassador yesterday as soon as the Senate finished unanimously voting for the former head of the CDC’s Global AIDS Program to take over former Ambassador Eric Goosby’s position as the head of PEPFAR. “Her focus, determination and dedication to research […]

Medicines Patent Pool, drugmaker agreement set to expand access to new antiretroviral

By on .

Dolutegravir agreement continue collaboration between British company and Unitaid-launched treatment access organization With a high barrier to drug-resistance, low production costs, low dosing and a potential for pediatric use, the new HIV drug dolutegravir, approved by the U.S. Food and Drug Administration in August, and for use among adults and adolescents by the European Medicines […]